ROTC personnel talk with civilian visitors during the dedication of the Lt. Tyler Brown Fitness Facility in the O'Keefe ...

In the latest trading session, Gilead Sciences (GILD) closed at $88.08, marking a -0.77% move from the previous day. This move lagged the S&P 500's daily gain of 0.16%. Elsewhere, the Dow saw a ...

Gilead Sciences has refiled for FDA approval of its HIV capsid inhibitor lenacapavir – which only needs to be dosed every six months – after the drug was rejected by the regulator in February.

Gilead Sciences (GILD) closed the latest trading day at $87.23, indicating a -1.05% change from the previous session's end. This move lagged the S&P 500's daily loss of 0.92%. Meanwhile ...

Gilead Sciences, Inc. (GILD), headquartered in Foster City, California, is a global biopharmaceutical leader known for its groundbreaking work in antiviral therapies. Valued at a market cap of $ ...

The treatment combines MSD’s islatravir with Gilead’s lenacapavir. Credit: Ground Picture via Shutterstock. Gilead Sciences and MSD are advancing ... According to GlobalData’s Pharma Intelligence ...

In this piece, we will look at where Gilead Sciences, Inc. (NASDAQ:GILD) ranks in the list. As the fourth quarter of 2024 settles in, the narrative surrounding stocks on Wall Street is starting to ...

Analyst Price Forecast Suggests 3.87% Downside As of September 24, 2024, the average one-year price target for Gilead ...

Gilead is with­draw­ing the ac­cel­er­at­ed ap­proval for its block­buster an­ti­body-drug con­ju­gate Trodelvy for blad­der can­cer af­ter it failed to im­prove sur­vival odds ...